Joshua D. Brandstadter

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

BACKGROUND: Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin-6 (IL-6) inhibitor, is the only FDA-approved treatment for adult patients with iMCD. Limited...